There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
From the FDA Drug Label
Includes anaphylactic reaction, anaphylactic shock, angioedema, dermatitis exfoliative generalized, drug hypersensitivity, eyelid oedema, face oedema, hypersensitivity, periorbital swelling, pharyngeal swelling, swelling face, toxic skin eruption, type I hypersensitivity, urticaria
- Composed of several similar terms The answer is: Yes, Rinvoq (upadacitinib) is associated with edema, as evidenced by the inclusion of eyelid oedema and face oedema in the list of adverse reactions. 1
From the Research
Edema Association with Rinvoq (Upadacitinib)
- Edema is mentioned in the context of atopic dermatitis treatment with upadacitinib in studies 2, 3.
- In the study 2, edema/papulation was one of the rash types assessed, and the results showed that upadacitinib was effective in reducing edema/papulation in patients with moderate-to-severe atopic dermatitis.
- The study 3 also evaluated the effectiveness of upadacitinib in reducing edema/papulation, among other rash types, in patients with moderate-to-severe atopic dermatitis who showed insufficient response to the initial 15 mg dose.
- However, there is no direct mention of edema as a side effect or association with upadacitinib in the other studies 4, 5, 6.
- The studies 2, 3 suggest that upadacitinib can be effective in reducing edema associated with atopic dermatitis, but do not provide information on edema as a potential side effect of the treatment.